LYKA LABS LTD. - 500259 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
The SEBI Appellate Tribunal, Mumbai Bench; wide its order dated 23rd November 2022, (received by the Company on 29th November 2022) has reduced the debarment period of the Company, from accessing the Capital Market and deal in the securities, from three years to the period already undergone. LYKA LABS LTD. - 500259 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015; we wish to inform you that the Company has issued duplicates share certificates LYKA LABS LTD. - 500259 - Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; please find enclosed herewith the disclosure on Related Party Transactions for the half year ended on 30th September 2022. LYKA LABS LTD. - 500259 - Outcome Of The Board Meeting Held On 9Th November 2022
The Standalone and Consolidated Unaudited Financial Results for the quarter and the half year ended 30th September 2022 LYKA LABS LTD. - 500259 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 9Th November 2022
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)Regulation, 2015; the Board of Directors in its meeting held today i. e.9th November 2022 considered and approved the following: 1. The Standalone and Consolidated Unaudited Financial Results for the quarter and the half year ended 30th September 2022 2. Noting resignation of Mr. Piyush G. Hindia, Company Secretary and Compliance officer of the Company. 3. Appointment of Mr. Kishore P. Shah, as Company Secretary and Compliance Officer of the Company 4. Appointment of Mr. Kishore P. Shah, as Nodal Officer under Investor Education and Protection Fund (IEPF) Rules, 2016. 5. The Board has considered acquisition of animal healthcare business from Agilis Healthcare Private Limited LYKA LABS LTD. - 500259 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 9Th November 2022.
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 ,inter alia, to consider and approve We wish to inform you that the meeting of Board of Directors of the Company is to be held on Wednesday, 9th November, 2022 at 125, Charkop Road, Charkop Industrial Estate, Kandivali West, Mumbai - 400 067, inter alia to consider and approve Standalone and Consolidated Un-Audited Financial Results for the Second Quarter and Half year ended on 30th September, 2022. LYKA LABS LTD. - 500259 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 please find enclosed Certificate for the quarter ended 30th September, 2022 received from M/s Link Intime India Pvt. Ltd., Registrar and Share Transfer Agent (RTA) of the Company. LYKA LABS LTD. - 500259 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Piyush G HindiaDesignation :- Company Secretary and Compliance Officer LYKA LABS LTD. - 500259 - Disclosure Under Regulation 7 (2) Read With Regulation 6(2) - Continual Disclosure Of SEBI (Prohibition Of Insider Trading) Regulations, 2015
I, Kunal N Gandhi S/o Late Shri. Narendra I Gandhi, Promoter/Promoter Group of Lyka Labs Limited; file herewith Form C for Disclosure under Regulation 7 (2) read with Regulation 6 (2) - Continual Disclosure of SEBI (Prohibition of Insider Trading) Regulations, 2015; for inter se transfer/transmission of 50,776 Equity Shares held in Lyka Labs Limited from N I Gandhi HUF to Kunal N Gandhi. LYKA LABS LTD. - 500259 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Company has received an intimation from M/s Link Intime India Private Limited (Registrar and Share Transfer Agent) on 11th October, 2022 for stop transfer of shares